期刊
CANCERS
卷 14, 期 19, 页码 -出版社
MDPI
DOI: 10.3390/cancers14194919
关键词
myeloma; second primary malignancy; SEER; risk; survival
类别
资金
- National Cancer Institute [1R01CA230339, 1R37CA255948]
As survival times for multiple myeloma (MM) patients continue to extend, the risk of developing a second primary malignancy (SPM) among MM survivors is a growing concern. This study evaluated the risk and survival of SPM among MM survivors from 1975 to 2018 using the Surveillance, Epidemiology, and End Results (SEER) 9 Registry Database. Factors such as age, sex, race, and time of MM diagnosis were found to be associated with SPM occurrence. The study suggests the need for site- and time-specific surveillance strategies to monitor SPM in high-risk MM patients.
Simple Summary Multiple myeloma (MM) is the second most common hematological malignancy with median age of diagnosis between 65-70 years. Since the introduction of multiple novel agents in MM management, survival times of MM patients continue to improve. Longer survival in patients with MM may be associated with increased risks of developing second primary malignancies (SPM). In this study, we investigated the risk factors associated with SPM and survival among MM survivors from 1975 to 2018. Age, race, and sex were important factors for the risk of SPM. Moreover, after SPM development, MM patients had a statistically significant 1.4-fold increased risk of death than MM patients without SPM. Site- and time-specific surveillance strategies surveillance strategies should be recommended to monitor SPM in high-risk MM patients. As the survival times for multiple myeloma (MM) patients continue to extend, the risk of a second primary malignancy (SPM) among MM survivors has become a topic of increasing concern within the medical community. The Surveillance, Epidemiology, and End Results (SEER) 9 Registry Database was used to evaluate the risk and survival of SPM among MM survivors from 1975 to 2018. The standardized incidence ratio (SIR), absolute excess risk (AER), and cumulative incidence (CMI) of SPM for MM risk were calculated. Survival and the CMI were estimated by using hazard ratios (HRs). Subgroup analyses were performed according to race, sex, age, time of myeloma diagnosis, and the SPM site. A total of 43,825 cases were recorded with the initial diagnosis of MM from 1975 to 2018. A total of 3101 (7.1%) patients developed 3407 SPMs. Solid tumors were decreased in patients with MM (SIR = 0.93; 95% CI = 0.90-0.97) compared to the general population, whereas the risk of hematological malignancy was increased (SIR = 1.90; 95% CI = 1.72-2.10). Taking death as a competing event, the CMI of SPM in the whole population was 7.38% at 10 years (6.11% solid and 1.27% hematologic). Factors associated with SPM occurrence were age, sex, race, and time of MM diagnosis. The survival of SPM patients from MM diagnosis was longer than that of patients without SPM (HR = 0.67, 95% CI = 0.58-0.63). The median survival time was 17 months from SPM diagnosis and 34 months from MM diagnosis (HR = 1.4, 95% CI = 1.35-1.46). Age, race, and sex were important factors for the risk of SPM. Site- and time-specific surveillance strategies should be recommended to monitor SPM in high-risk MM patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据